Vision disorder

Summary

Vision disorder (MONDO:0021084) is a disease (an umbrella term covering 7 Mondo subtypes) with 7 cohort genes (11 GWAS associations across 8 studies) and 67 clinical trials. Top therapeutic interventions include cyclopentolate, fluorescein, and tropicamide.

At a glance

• Umbrella term: 7 Mondo subtypes
• Cohort genes: 7
• GWAS associations: 11
• Clinical trials: 67

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vision disorder
Mondo ID	MONDO:0021084
MeSH	D014786
NCIT	C35126
SNOMED CT	95677002
UMLS	C0042790
MedGen	12103
MedDRA	10047518
Is cancer (heuristic)	no

Also known as: disorder of vision · disorder of visual system · vision disorder · visual disorder · visual system disorder

Data availability: 11 GWAS associations (8 studies).

Disease family

An umbrella term covering 7 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › perceptual disorders › vision disorder

Related subtypes (8): apraxia, vestibular disorder, agnosia, inherited retinal dystrophy, hearing disorder, auditory perceptual disorders, allesthesia, hallucinogen-persisting perception disorder

Subtypes (7): visual agnosia, amblyopia, binocular vision disease, color vision disorder, visual pathway disorder, blindness (disorder), Alice in Wonderland syndrome

Genetics & variants

GWAS landscape

11 GWAS associations across 8 studies. Top hits map to 9 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs12409657	2e-07	TRABD2B	?
rs9358951	6e-07	GCM2	?
rs9791502	9e-07	SDK1	?
rs2101938	1e-06	MYH10 - CCDC42	?
rs1245489	2e-06	SLC44A3-AS1	?
rs9945284	2e-06	RPL12P40 - RN7SKP182	?
rs12419121	4e-06	RDX, LINC02715	?
rs9752743	6e-06	LALTOP - PXDN	?
rs38098	8e-06	MAGI2	?
rs4617585	9e-06	ANO5	?
rs4789955	9e-06	RBFOX3	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90477701	Verma A	2024	9,806	430,739	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90473445	UK Biobank Whole-Genome Sequencing Consortium	2025	1,644	456,796	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90477700	Verma A	2024	1,516	118,245	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90481108	Verma A	2024	1,516	118,245	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477699	Verma A	2024	976	57,683	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90435996	Zhou W	2018	732	405,654	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90652178	Liu TY	2025	425	227,729	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST011826	Yoshimura K	2021	0	0	A web-based survey on various symptoms of computer vision syndrome and the genetic understanding based on a multi-trait genome-wide association study.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	11

MAF distribution

Bucket	Variants
common (>=0.05)	11
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	7
intergenic_variant	4

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs12409657	1	47767766	C>G,T	0.05	intron_variant	TRABD2B	2e-07	Tier 4: intronic/intergenic
rs9358951	6	10878459	T>A,C	0.05	intron_variant	GCM2	6e-07	Tier 4: intronic/intergenic
rs9791502	7	3571976	G>A,C	0.05	intron_variant	SDK1	9e-07	Tier 4: intronic/intergenic
rs2101938	17	8717311	C>G,T	0.05	intergenic_variant	MYH10 - CCDC42	1e-06	Tier 4: intronic/intergenic
rs1245489	1	94608899	G>A,C	0.05	intron_variant	SLC44A3-AS1	2e-06	Tier 4: intronic/intergenic
rs9945284	18	38925354	G>A,C,T	0.05	intergenic_variant	RPL12P40 - RN7SKP182	2e-06	Tier 4: intronic/intergenic
rs12419121	11	110064827	G>A	0.05	intergenic_variant	RDX, LINC02715	4e-06	Tier 4: intronic/intergenic
rs9752743	2	1622620	G>A	0.05	intron_variant	LALTOP - PXDN	6e-06	Tier 4: intronic/intergenic
rs38098	7	78609449	T>A,C	0.05	intron_variant	MAGI2	8e-06	Tier 4: intronic/intergenic
rs4617585	11	21861312	T>A,C	0.05	intergenic_variant	ANO5	9e-06	Tier 4: intronic/intergenic
rs4789955	17	79206748	G>A	0.05	intron_variant	RBFOX3	9e-06	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 7 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
MAGI2	Orphanet:656	Hereditary steroid-resistant nephrotic syndrome
ANO5	Orphanet:206549	Anoctamin-5-related limb-girdle muscular dystrophy R12
ANO5	Orphanet:206599	Isolated asymptomatic elevation of creatine phosphokinase
ANO5	Orphanet:399096	Distal anoctaminopathy
ANO5	Orphanet:53697	Gnathodiaphyseal dysplasia
ANO5	Orphanet:689021	Asymptomatic hyperCKemia-myalgia-rhabdomyolysis syndrome
RDX	Orphanet:90636	Rare autosomal recessive non-syndromic sensorineural deafness type DFNB

Cohort genes → proteins

7 cohort genes, 7 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	7

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
MAGI2	HGNC:18957	ENSG00000187391	Q86UL8	Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2	gwas
SDK1	HGNC:19307	ENSG00000146555	Q7Z5N4	Protein sidekick-1	gwas
RBFOX3	HGNC:27097	ENSG00000167281	A6NFN3	RNA binding protein fox-1 homolog 3	gwas
ANO5	HGNC:27337	ENSG00000171714	Q75V66	Anoctamin-5	gwas
SLC44A3	HGNC:28689	ENSG00000143036	Q8N4M1	Choline transporter-like protein 3	gwas
TRABD2B	HGNC:44200	ENSG00000269113	A6NFA1	Metalloprotease TIKI2	gwas
RDX	HGNC:9944	ENSG00000137710	P35241	Radixin	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
MAGI2	Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2	Seems to act as a scaffold molecule at synaptic junctions by assembling neurotransmitter receptors and cell adhesion proteins.
SDK1	Protein sidekick-1	Adhesion molecule that promotes lamina-specific synaptic connections in the retina.
RBFOX3	RNA binding protein fox-1 homolog 3	Pre-mRNA alternative splicing regulator.
ANO5	Anoctamin-5	Plays a role in plasma membrane repair in a process involving annexins.
TRABD2B	Metalloprotease TIKI2	Metalloprotease that acts as a negative regulator of the Wnt signaling pathway by mediating the cleavage of the 8 N-terminal residues of a subset of Wnt proteins.
RDX	Radixin	Probably plays a crucial role in the binding of the barbed end of actin filaments to the plasma membrane.

Protein-family classification

Druggable: 2 · Difficult: 0 · Unknown: 5 · Druggable fraction: 0.29

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Antibody/Immunoglobulin	1	4.2×	0.332
Kinase	1	4.0×	0.332
Other/Unknown	5	1.3×	0.332

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
MAGI2	Kinase	yes		WW_dom, PDZ, Guanylate_kin-like_dom
SDK1	Antibody/Immunoglobulin	yes		Ig_sub2, Ig_sub, FN3_dom
RBFOX3	Other/Unknown	no		RRM_dom, Nucleotide-bd_a/b_plait_sf, RBFOX1-3
ANO5	Other/Unknown	no		Anoctamin, Anoct_dimer, Anoctamin_TM
SLC44A3	Other/Unknown	no		Choline_transptr-like
TRABD2B	Other/Unknown	no		TraB/PrgY/GumN_fam, TIKI1/2-like
RDX	Other/Unknown	no		FERM_domain, Ez/rad/moesin-like, Moesin_tail_sf

Expression context

Cohort genes with no expression data: 0.

6 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	7
unknown	0

Top tissues across cohort

Tissue	Cohort genes
popliteal artery	2
tibial artery	2
Brodmann (1909) area 23	1
calcaneal tendon	1
corpus callosum	1
decidua	1
cerebellar cortex	1
cerebellar hemisphere	1
right hemisphere of cerebellum	1
cardiac muscle of right atrium	1
left ventricle myocardium	1
vastus lateralis	1
ileal mucosa	1
mucosa of transverse colon	1
rectum	1
right coronary artery	1
adrenal tissue	1
right adrenal gland cortex	1
visceral pleura	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
MAGI2	267	ubiquitous	marker	calcaneal tendon, corpus callosum, Brodmann (1909) area 23
SDK1	183	broad	marker	popliteal artery, decidua, tibial artery
RBFOX3	177	broad	marker	right hemisphere of cerebellum, cerebellar cortex, cerebellar hemisphere
ANO5	220	broad	marker	cardiac muscle of right atrium, left ventricle myocardium, vastus lateralis
SLC44A3	212	broad	marker	mucosa of transverse colon, rectum, ileal mucosa
TRABD2B	148	broad	yes	popliteal artery, tibial artery, right coronary artery
RDX	295	ubiquitous	marker	adrenal tissue, right adrenal gland cortex, visceral pleura

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
RBFOX3	4,442
MAGI2	3,246
RDX	3,167
SLC44A3	921
SDK1	806
ANO5	790
TRABD2B	256

Structural data

PDB: 2 · AlphaFold-only: 5 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
MAGI2	Q86UL8	5
RDX	P35241	2

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
ANO5	Q75V66	82.22
SLC44A3	Q8N4M1	81.32
SDK1	Q7Z5N4	72.92
TRABD2B	A6NFA1	70.11
RBFOX3	A6NFN3	62.27

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 22. Enrichment computed across 7 evidence-associated genes (6 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
SDK interactions	1	951.7×	0.012	SDK1
Cell-Cell communication	2	45.9×	0.012	MAGI2, SDK1
SLC-mediated bile acid transport	1	271.9×	0.027	SLC44A3
Induction of Cell-Cell Fusion	1	146.4×	0.037	ANO5
NPAS4 regulates expression of target genes	1	82.8×	0.046	RBFOX3
Nephrin family interactions	1	79.3×	0.046	MAGI2
Synthesis of PC	1	68.0×	0.046	SLC44A3
Late SARS-CoV-2 Infection Events	1	48.8×	0.053	ANO5
Cell-cell junction organization	1	41.4×	0.053	SDK1
Regulation of clotting cascade	1	38.8×	0.053	ANO5
Recycling pathway of L1	1	37.3×	0.053	RDX
Sensory processing of sound by outer hair cells of the cochlea	1	34.0×	0.053	RDX
Cell junction organization	1	31.2×	0.054	SDK1
Sensory processing of sound by inner hair cells of the cochlea	1	27.2×	0.057	RDX
Stimuli-sensing channels	1	22.7×	0.064	ANO5
Ion channel transport	1	16.0×	0.084	ANO5
SARS-CoV-2 Infection	1	13.4×	0.094	ANO5
SARS-CoV Infections	1	9.2×	0.126	ANO5
Viral Infection Pathways	1	5.1×	0.208	ANO5
Transport of small molecules	1	4.2×	0.229	ANO5
Infectious disease	1	4.1×	0.229	ANO5
Disease	1	2.2×	0.380	ANO5

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
regulation of adherens junction organization	1	2407.4×	0.020	RDX
regulation of postsynaptic neurotransmitter receptor diffusion trapping	1	802.5×	0.020	RDX
regulation of Rap protein signal transduction	1	601.9×	0.020	RDX
establishment of protein localization to plasma membrane	1	481.5×	0.020	RDX
regulation of organelle assembly	1	481.5×	0.020	RDX
microvillus assembly	1	267.5×	0.020	RDX
positive regulation of early endosome to late endosome transport	1	267.5×	0.020	RDX
regulation of dendritic spine development	1	240.7×	0.020	SDK1
positive regulation of protein localization to early endosome	1	240.7×	0.020	RDX
podocyte development	1	218.9×	0.020	MAGI2
cellular response to thyroid hormone stimulus	1	218.9×	0.020	RDX
obsolete protein kinase A signaling	1	200.6×	0.020	RDX
negative regulation of activin receptor signaling pathway	1	200.6×	0.020	MAGI2
nerve growth factor signaling pathway	1	185.2×	0.020	MAGI2
apical protein localization	1	141.6×	0.023	RDX
behavioral response to cocaine	1	120.4×	0.023	SDK1
phosphatidylcholine biosynthetic process	1	114.6×	0.023	SLC44A3
barbed-end actin filament capping	1	114.6×	0.023	RDX
establishment of endothelial barrier	1	109.4×	0.023	RDX
SMAD protein signal transduction	1	104.7×	0.023	MAGI2
positive regulation of receptor internalization	1	100.3×	0.023	MAGI2
retina layer formation	1	92.6×	0.023	SDK1
cellular response to platelet-derived growth factor stimulus	1	92.6×	0.023	RDX
receptor clustering	1	89.2×	0.023	MAGI2
plasma membrane repair	1	83.0×	0.023	ANO5
clathrin-dependent endocytosis	1	83.0×	0.023	MAGI2
nervous system development	2	13.1×	0.023	MAGI2, RBFOX3
cellular response to nerve growth factor stimulus	1	66.9×	0.027	MAGI2
Wnt signaling pathway, planar cell polarity pathway	1	65.1×	0.027	MAGI2
positive regulation of G1/S transition of mitotic cell cycle	1	57.3×	0.029	RDX

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 7

Druggability breadth: 1 of 7 evidence-associated genes (14%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
MAGI2	0	0
SDK1	0	0
RBFOX3	0	0
ANO5	0	0
SLC44A3	0	0
TRABD2B	0	0
RDX	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
RDX	1	Binding:1

Pharmacogenomics

Cohort genes with a PharmGKB record: 7; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	1	MAGI2
D	Druggable family + AlphaFold only, no drug	1	SDK1
E	Difficult family or no structure, no drug	5	RBFOX3, ANO5, SLC44A3, TRABD2B, RDX

Undrugged target profiles

7 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
MAGI2	0	—
SDK1	0	—
RBFOX3	0	—
ANO5	0	—
SLC44A3	0	—
TRABD2B	0	—
RDX	1	—

Clinical trials & evidence

Clinical trials

Clinical trials: 67.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	52
PHASE2/PHASE3	4
PHASE1/PHASE2	4
PHASE4	2
PHASE3	2
PHASE2	1
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01546402	PHASE4	COMPLETED	Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
NCT06077682	PHASE4	UNKNOWN	Cycloplegic Refraction in Pediatric Patients With Esotropia
NCT03913143	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
NCT06891443	PHASE3	RECRUITING	Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
NCT07140783	PHASE3	RECRUITING	OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity
NCT04855045	PHASE2/PHASE3	UNKNOWN	An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.
NCT05158296	PHASE2/PHASE3	TERMINATED	Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
NCT05176717	PHASE2/PHASE3	TERMINATED	Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)
NCT04123626	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
NCT06627179	PHASE2	RECRUITING	Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT03780257	PHASE1/PHASE2	COMPLETED	Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene
NCT03872479	PHASE1/PHASE2	UNKNOWN	Single Ascending Dose Study in Participants With LCA10
NCT03913130	PHASE1/PHASE2	TERMINATED	Extension Study to Study PQ-110-001 (NCT03140969)
NCT02540122	PHASE1	COMPLETED	Pilot Clinical Evaluation of Approved Contact Lenses
NCT06451172	EARLY_PHASE1	RECRUITING	Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
NCT02911805	Not specified	ACTIVE_NOT_RECRUITING	Bridging Animal and Human Models of Exercise-induced Visual Rehabilitation
NCT05600140	Not specified	RECRUITING	Viewing Strategy Training in Children With (Cerebral) Visual Impairment
NCT05921240	Not specified	ENROLLING_BY_INVITATION	Unmet Needs, Barriers and Facilitators to Vision Services for Children and Adolescents With Special Vision
NCT06098677	Not specified	NOT_YET_RECRUITING	Effect of Carotenoids Supplementation on Visual Function in Chinese Subjects
NCT06500728	Not specified	RECRUITING	Visual Involvement in Giant Cell Arteritis
NCT06882434	Not specified	NOT_YET_RECRUITING	Holistic Integration for Healthy Longevity and Aging in Place
NCT06992622	Not specified	RECRUITING	Zhejiang Adolescent Spine and Vision Health Cohort: A Longitudinal Database Analysis
NCT07085533	Not specified	RECRUITING	Natural History Study of Inherited Retinal Diseases
NCT07559292	Not specified	ENROLLING_BY_INVITATION	Implementing Artificial Intelligence to Prevent Vision Loss From Diabetes
NCT00013936	Not specified	COMPLETED	A Novel Acuity Testing Method
NCT00395122	Not specified	COMPLETED	Optical Coherence Tomography Measurements in Eyes With Band Atrophy
NCT00985231	Not specified	COMPLETED	Performance Evaluation of Contact Lenses Among a Population of Adapted Contact Lens Wearers
NCT01318577	Not specified	COMPLETED	Study of A New Contact Lens Cleaning and Disinfecting Solution
NCT01698749	Not specified	COMPLETED	Effect of Intravitreal Long Acting Dexamethasone Implant, Ozurdex in Patients With Diabetic Macular Edema
NCT01698788	Not specified	COMPLETED	Effect of Intraoperative Dexamethasone Implant in Taut Posterior Hyaloid Removal in Diabetic Macular Edema
NCT02234635	Not specified	UNKNOWN	Visual Quality Change of Eyes Implanted With Diffractive Multifocal Intraocular Lens After Cataract Surgery
NCT02485054	Not specified	COMPLETED	A Predictive Score for the Ischemic Etiology of a Transient Visual Disturbances (VASCO)
NCT02529098	Not specified	WITHDRAWN	Modification in Cortical Activation in Pseudophakic Patients With Visual Difficulties After a Multifocal Implantation
NCT02543528	Not specified	COMPLETED	A Clinical Trial to Evaluate Investigational Silicone Hydrogel Contact Lenses Worn Continuously for One Week
NCT02571647	Not specified	COMPLETED	Evaluation of Screening for Visual Disorders of the Old Subject in Consultation Memory
NCT02595502	Not specified	COMPLETED	Clinical Evaluation of Two Silicone Hydrogel Daily Disposable Contact Lenses
NCT02625233	Not specified	COMPLETED	Clinical Long-Term Evaluation of Approved and Investigational Contact Lenses
NCT02669095	Not specified	COMPLETED	Clinical Evaluation of Approved and Investigational Contact Lenses
NCT02679313	Not specified	WITHDRAWN	Effect of Lens Presentation on the Clinical Oculomotor Assessment at Near
NCT02680223	Not specified	COMPLETED	Efficacy of Coloured Overlays and Lenses for Reading Difficulty

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CYCLOPENTOLATE	4	1
FLUORESCEIN	4	1
TROPICAMIDE	4	1
COMFILCON A	3	1
ETAFILCON A	3	1
SEPOFARSEN	2	4
BRINRETIGENE VESGEDPARVOVEC	2	1
ISOXAFLUTOLE	2	1
ULTEVURSEN	2	1
CHEMBL1457550	0	1
CHEMBL177756	0	1